43 - Lipid and lipoprotein metabolism: Miscellaneous| Volume 235, ISSUE 2, e203, August 2014

Pioglitazone treatment may lead to anti-atherogenic alterations of lipoproteins through increasing serum adiponectin in statin-treated diabetes patients

      Objectives: Pioglitazone (PGZ), an insulin-sensitizing agent, has been reported to alter circulating lipids, including triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C), and adiponectin (ADPN) levels. However, clinical effects of PGZ on the quality of lipoproteins have not been fully defined. We aimed to clarify the clinical association of PGZ treatment with the ratios of lipoproteins to apolipoproteins and the ADPN levels in statin-treated diabetes patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect